Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Non-Current Liabilities (2018 - 2025)

Corcept Therapeutics' Other Non-Current Liabilities history spans 8 years, with the latest figure at $15.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 7.75% year-over-year to $15.2 million; the TTM value through Dec 2025 reached $15.2 million, up 7.75%, while the annual FY2025 figure was $15.2 million, 7.75% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $15.2 million at Corcept Therapeutics, up from $14.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $15.7 million in Q2 2025 and bottomed at $403000.0 in Q2 2021.
  • The 5-year median for Other Non-Current Liabilities is $10.1 million (2023), against an average of $8.7 million.
  • The largest annual shift saw Other Non-Current Liabilities increased 1.77% in 2021 before it soared 2124.21% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $409000.0 in 2021, then skyrocketed by 2124.21% to $9.1 million in 2022, then increased by 13.3% to $10.3 million in 2023, then soared by 36.64% to $14.1 million in 2024, then increased by 7.75% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Other Non-Current Liabilities are $15.2 million (Q4 2025), $14.1 million (Q3 2025), and $15.7 million (Q2 2025).